MA-PRECISELY
14.12.2022 15:02:06 CET | Business Wire | Press release
Precisely, the global leader in data integrity, today announced the regional expansion of its unique location identifier, the PreciselyID, for its World Points of Interest (POI) data offering. Points of interest located in the US, Canada, Belgium, Luxembourg, the Netherlands, United Kingdom, Ireland, France, Sweden, and Singapore now benefit from accurate, standardized, and meaningful data – allowing businesses to streamline location-based decision-making across multiple regions of operation.
Disruption from the pandemic and other world events has had a lasting impact on many aspects of day-to-day life, including shopping habits, work location, and travel behaviors – making it even more important for businesses to be able to access accurate and current data on points of interest.
But keeping POI data fresh is no small feat, even for companies such as Google, who recently revealed that it removed seven million fake business profiles and prevented 12 million from being created throughout 2021 alone. Standardizing POI data is just as difficult; differences in address standards, language, character variations, or a lack of accurate address data, make it challenging for companies to effectively operationalize data from multiple regions.
Unlike other address identifiers on the market that associate a business name to an address, the PreciselyID is appended to both the location’s coordinates and the address and will remain constant over time. If a business closes and a new one opens in the same location, Precisely processes this change so that the PreciselyID will reflect the attributes for the new point of interest. As a result, businesses that use addresses as a primary data input will always have access to the most accurate data about any given location, enabling insights without needing geospatial tools or specialized skillsets.
“Businesses today need reliable answers about the world around them. If a clothing boutique closes, and the location becomes a coffee shop, it has an impact on the level of traffic, and types of shoppers, workers, and visitors to that area,” said Dan Adams, SVP – Data and Operations, at Precisely. “That’s why we associate the PreciselyID with an address and location, so our customers always have access to accurate, verified, and standardized data for detailed insights that matter to their business.”
POIs enabled with the PreciselyID have been cleansed, standardized, and verified by Precisely’s best-in-class geo addressing. As a result, organizations can quickly enrich records with accurate data while saving processing time and simplifying complex geospatial analysis. With access to a portfolio of over 400 datasets containing more than 9,000 attributes, Precisely customers can increase the accuracy, usability, and overall value of their business data and build context for faster, more confident decisions.
The regional expansion unlocks new capabilities for a wide variety of industries, including:
- Retail – Leveraging location insights for site selection and management, locating competition and demand to identify opportunities for new stores or consolidation
- Financial Services - Validating merchant data and achieving a 360-degree view of the changing landscape they operate in
- Insurance – Helping to understand adjacent risk – including whether a property is located near to a high-risk building, such as a chemical plant
- Telecommunications – Obtaining a full view into the places where people congregate, supporting telcos with their goal of providing high levels of coverage and keeping customers connected
- Public Sector – Understanding where people work, shop, and spend their leisure time, enhancing planning for public transport networks, emergency services, and planning
Precisely expects further expansion, with support for more countries added in the future. Learn more about how to seamlessly connect addresses, properties, and POI data with the PreciselyID here.
About Precisely
Precisely is the global leader in data integrity, providing accuracy, consistency, and context in data for 12,000 customers in more than 100 countries, including 99 of the Fortune 100. Precisely’s data integration, data quality, data governance, location intelligence, and data enrichment products power better business decisions to create better outcomes. Learn more at www.precisely.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005542/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release
Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –
The Biggest Predictor of Business Growth Is Behavior30.4.2026 09:00:00 CEST | Press release
New IDEO research reveals a gap in the behaviors that most drive growth: long-term vision, rapid experimentation, and team autonomy—with only 10% of leaders saying their company excels at the combination. IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media &
Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 00:22:00 CEST | Press release
Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 22:30:00 CEST | Press release
Surgeon-Founded Brand Anchored by Innovative NAC Y2™ Technology The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
